Skip to main content

Table 5 Univariate logistic regression analysis examining the influence of patient factors on pathologic complete response (pCR)

From: Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment

Values

Univariate analysis OR (95% CI)

P

Multivariate analysis OR (95% CI) (Model 1*)

P

Multivariate analysis OR (95% CI) (Model 2†)

P

Age > 60

1.28 (0.64–2.58)

0.481

    

Male

1.74 (0.66–4.59)

0.265

    

BMI ≤ 23.9

0.93 (0.46–1.89)

0.845

    

Poor differentiation

1.75 (0.75–4.11)

0.196

    

Linitis plastica

NA

NA

    

NACT cycles ≥ 4

3.54 (1.56–8.05)

0.002

3.09 (1.30–7.33)

0.011

3.20 (1.36–7.55)

0.008

Triplet drug

4.73 (1.24–18.08)

0.023

3.09 (0.72–13.31)

0.130

3.31 (0.78–13.98)

0.103

CEA ≤ 5.72

2.06 (0.32–6.90)

0.241

    

CA19-9 ≤ 15.00

1.53 (0.73–3.21)

0.259

    

CA72-4 ≤ 2.60

2.29 (1.11–4.72)

0.025

  

2.32 (1.11–4.84)

0.025

Post-NACT CTM

      

 0

4.33 (1.39–13.49)

0.01

4.19 (1.33–13.14)

0.014

  

 1

2.88 (0.94–8.77)

0.060

2.75 (0.89–8.50)

0.078

  

 2/3

1.00

 

1.00

   
  1. *Model 1: adjusted for NACT cycles, triplet regimen and post-NACT CTM score; †Model 2: adjusted for NACT cycles, triplet regimen CEA, CA19-9 and CA72-4; BMI, body mass index; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate antigen 72-4; CEA, carcinoembryonic antigen; CI, confidence interval; CTM, combination of tumor markers; OR, odds ratio; CI, confidence interval